Peter Linde - Jun 1, 2021 Form 4 Insider Report for Morphic Holding, Inc. (MORF)

Role
Chief Medical Officer
Signature
/s/ Robert Farrell as attorney-in-fact for Peter Linde
Stock symbol
MORF
Transactions as of
Jun 1, 2021
Transactions value $
-$299,110
Form type
4
Date filed
6/3/2021, 07:15 PM
Next filing
Sep 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MORF Common Stock Sale -$231K -4.65K -43.85% $49.72 5.95K Jun 1, 2021 Direct F1, F2
transaction MORF Common Stock Sale -$68K -1.35K -22.72% $50.30 4.6K Jun 1, 2021 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.06 to $50.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.06 to $50.87 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.